The average one-year price target for Century Therapeutics (NasdaqCM:IPSC) has been revised to $4.08 / share. This is a ...
The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Leerink Partners on November 17, 2025. The analyst firm set a price target for $2.00 expecting IPSC to rise to within 12 ...
Shares of Century Therapeutics, Inc. (IPSC) have gained 9.7% over the past four weeks to close the last trading session at $5, but there could still be a solid upside left in the stock if short-term ...
Investing.com - Leerink Partners has lowered its price target on Fate Therapeutics (NASDAQ:FATE) to $7.00 from $12.00 while maintaining an Outperform rating on the stock. The new target still ...
Latent cardiovascular toxicity issues continue to plague late-stage drug discovery efforts, as well as commercially launched pharmaceutical success. Many current in vitro models lack, or incompletely ...
-- Data supporting selection of ROR1 for CB-020 and armoring strategies for Caribou’s CAR-NK cell platform to be presented at AACR-JCA Conference today -- -- Caribou is using its chRDNA next-gen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results